FindTrial
Sign In

Case studies of patient who took Tab Ribociclib and Palbociclib and have suffered vitiligo complaint

A case series to report CDK4/6 induced Vitiligo. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/01/079700
Enrollment
6
Registered
2025-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Control Intervention1: Not applicable: Not applicable

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Hormone positive, HER 2 negative breast cancer patients, who are receiving CDK4/6 inhibitors.

Exclusion criteria

Exclusion criteria: Not willing participants

Design outcomes

Primary

MeasureTime frame
Main study: The purpose of the study is to report the adverse event Vitiligo in patients taking CDK4/6 inhibitor. The optional part: The aim of this study is to dermatologically define and histologically characterize this drug induced vitiligo.Timepoint: 3 MONTHS—

Secondary

MeasureTime frame
Not applicableTimepoint: 00—

Countries

India

Contacts

Public ContactYogesh Kembhavi

Tata Memorial Center

sudeepgupta04@yahoo.com02224177201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026